KRAS and neoplasm: Additionally, while the direct target of RGS remains controversial, our research verified that RGS significantly disrupted activated RAS signaling in both CRC cell lines and patient’s tumor tissues, and that this provided a theoretical basis for the potential clinical application of RGS to treat KRAS-mutant CRC.